Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ELITE CLINICAL LABORATORY, INC

NPI: 1215055256 · HOUSTON, TX 77063 · Clinical Medical Laboratory · NPI assigned 03/27/2007

$367K
Total Medicaid Paid
43,133
Total Claims
38,651
Beneficiaries
62
Codes Billed
2020-10
First Month
2024-11
Last Month

Provider Details

Authorized OfficialHARPER, CHAD (OWNER)
NPI Enumeration Date03/27/2007

Related Entities

Other providers sharing the same authorized official: HARPER, CHAD

ProviderCityStateTotal Paid
ELITE BIO REFERENCE LABORATORY LLC TAMPA FL $167K
REDWOOD LAB SERVICES, LLC HOUSTON TX $75K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 110 $0.00
2022 13,191 $123K
2023 15,095 $49K
2024 14,737 $196K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 2,358 2,108 $180K
87631 1,815 1,641 $33K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1,064 762 $25K
87481 2,210 1,959 $18K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,328 2,165 $17K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 1,253 1,104 $8K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1,064 762 $8K
87640 2,132 1,939 $7K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 2,135 1,942 $7K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 399 386 $6K
87653 2,081 1,892 $6K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,228 2,075 $6K
87556 1,673 1,509 $4K
87486 1,826 1,642 $4K
87581 1,826 1,642 $4K
87541 1,826 1,642 $4K
87532 1,673 1,509 $3K
87496 1,573 1,416 $3K
87500 1,215 1,047 $3K
87498 1,814 1,630 $3K
87150 252 201 $3K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 158 140 $3K
87503 1,243 1,094 $2K
87641 913 816 $2K
86413 997 871 $2K
81400 126 126 $624.79
81434 213 212 $585.95
81232 28 28 $541.23
81335 28 28 $541.22
81321 86 86 $479.36
81226 14 14 $470.22
81225 14 14 $443.71
87634 1,119 973 $429.26
81306 14 14 $405.11
81381 14 14 $357.92
81508 175 175 $324.59
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 15 15 $312.84
81238 20 20 $240.00
81227 14 14 $235.67
81283 14 14 $102.01
87551 551 516 $76.98
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 625 574 $56.02
87561 549 515 $56.02
81181 206 205 $10.86
81339 112 112 $0.00
81419 197 196 $0.00
81317 29 29 $0.00
81333 116 116 $0.00
87563 25 14 $0.00
81307 16 16 $0.00
81249 16 16 $0.00
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 50 33 $0.00
81430 149 149 $0.00
82387 167 166 $0.00
81250 110 110 $0.00
81254 149 149 $0.00
81209 16 16 $0.00
81242 15 15 $0.00
81298 17 17 $0.00
87511 25 14 $0.00
81279 18 18 $0.00
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 25 14 $0.00